The link you have selected will take you away from the TAVNEOS® (avacopan) website to one that is not owned or controlled by ChemoCentryx. ChemoCentryx accepts no responsibility for the content of linked sites.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click “OK” if you are a healthcare professional.
Based on your location, you are being redirected to the website of our licensee Vifor Fresenius Medical Care Renal Pharma Ltd. CCXI does not have responsibility for, or control of, the contents, availability, operation, or performance of the website.
TAVNEOS® is a prescription medicine for adult patients with severe active GPA or MPA that is added to your current
treatment. It is not known if TAVNEOS® is safe and effective for children under the age of 18.
Patients may be eligible for TAVNEOS® when ALL of the following criteria are met:
1. Adults diagnosed with the following types of severe active ANCA-associated vasculitis:
2. Patient is currently (any of the below):
Talk with your doctor about whether TAVNEOS® is right for you.
Keep TAVNEOS® and all medicines out of reach of children.
If you have taken too much TAVNEOS®, call your doctor or a Poison Control Center, or go to the nearest hospital emergency room.
Your healthcare provider may prescribe other medicines to treat your disease.
TAVNEOS can cause serious side effects, including:
Your healthcare provider will do blood tests to check how well your liver is working before starting and during your treatment with TAVNEOS.
The most common side effects of TAVNEOS include:
TAVNEOS is a prescription medicine that is used with other medicines (such as glucocorticoids) to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA], formerly known as Wegener’s granulomatosis, and microscopic polyangiitis [MPA]).
TAVNEOS is available as a 10 mg capsule.
You are encouraged to report negative side effects to Amgen at 1-833-828-6367 or to the FDA by
visiting www.fda.gov/medwatch or calling 1-800-332-1088.